Columbus Circle Investors Buys Shares of 196,621 Eli Lilly And Co (LLY)

Share on StockTwits

Columbus Circle Investors bought a new stake in shares of Eli Lilly And Co (NYSE:LLY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 196,621 shares of the company’s stock, valued at approximately $21,099,000.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC raised its holdings in shares of Eli Lilly And Co by 172.9% during the second quarter. FMR LLC now owns 1,188,301 shares of the company’s stock valued at $101,398,000 after acquiring an additional 752,864 shares during the last quarter. Greenleaf Trust increased its holdings in shares of Eli Lilly And Co by 37.7% in the second quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock valued at $838,000 after purchasing an additional 2,686 shares during the last quarter. Raymond James & Associates increased its holdings in shares of Eli Lilly And Co by 13.4% in the second quarter. Raymond James & Associates now owns 434,915 shares of the company’s stock valued at $37,112,000 after purchasing an additional 51,504 shares during the last quarter. GAM Holding AG increased its holdings in shares of Eli Lilly And Co by 481.3% in the second quarter. GAM Holding AG now owns 18,463 shares of the company’s stock valued at $1,575,000 after purchasing an additional 15,287 shares during the last quarter. Finally, Intrust Bank NA increased its holdings in shares of Eli Lilly And Co by 6.5% in the second quarter. Intrust Bank NA now owns 9,849 shares of the company’s stock valued at $840,000 after purchasing an additional 597 shares during the last quarter. 76.36% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently commented on LLY shares. Morgan Stanley increased their price target on Eli Lilly And Co from $93.00 to $102.00 and gave the company an “equal weight” rating in a report on Tuesday, July 31st. TheStreet cut Eli Lilly And Co from a “b” rating to a “c+” rating in a report on Friday, August 24th. Guggenheim started coverage on Eli Lilly And Co in a report on Monday, October 8th. They issued a “buy” rating for the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $128.00 price target on shares of Eli Lilly And Co in a report on Wednesday, October 17th. Finally, Barclays reaffirmed an “overweight” rating and issued a $112.00 price target (up previously from $107.00) on shares of Eli Lilly And Co in a report on Tuesday, September 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $111.53.

In related news, insider Donald A. Zakrowski sold 600 shares of the stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $105.57, for a total value of $63,342.00. Following the completion of the transaction, the insider now directly owns 3,530 shares in the company, valued at $372,662.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $102.15, for a total value of $19,919,250.00. Following the completion of the transaction, the insider now owns 120,735,804 shares of the company’s stock, valued at $12,333,162,378.60. The disclosure for this sale can be found here. Insiders sold 1,570,271 shares of company stock valued at $162,683,202 over the last quarter. 0.11% of the stock is currently owned by company insiders.

NYSE:LLY opened at $107.40 on Tuesday. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $114.26 billion, a P/E ratio of 25.09, a P/E/G ratio of 1.73 and a beta of 0.29.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 annualized dividend and a yield of 2.09%. Eli Lilly And Co’s payout ratio is 52.57%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: What are the economic characteristics of a bear market?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply